Adenosine A2a Receptor Antagonist for NSCLC Immune Evasion
Solution Overview
Problem
Current treatments for non-small cell lung cancer (NSCLC) have limited efficacy and are associated with significant toxicity, and there is a need for novel therapies that can effectively target the adenosine-mediated immunosuppressive mechanisms used by tumors to evade immune surveillance.
Innovation Solution
The development of 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine, its pharmaceutically acceptable salts, and co-crystals, which act as potent adenosine A2a receptor antagonists, combined with immunotherapeutic agents like PD-1 and PD-L1 inhibitors to boost the immune system and inhibit tumor evasion mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for non-small cell lung cancer are used, then cancer therapy is provided, but efficacy is limited and toxicity is significant
Solution Approach 1:
The patent applies parameter changes by developing a novel chemical compound (5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine) with specific molecular structure parameters that selectively target adenosine A2a receptors. This compound exhibits enhanced potency and selectivity compared to existing treatments, achieving better anti-tumor efficacy while reducing off-target toxicity through optimized chemical parameters
Solution Approach 2:
The invention uses the adenosine A2a receptor antagonist as an intermediary substance that blocks the immunosuppressive adenosinergic pathway in the tumor microenvironment. This intermediary compound prevents adenosine from suppressing immune cells, thereby restoring immune-mediated anti-tumor activity without directly cytotoxic to cancer cells, reducing treatment toxicity
2Reliability
If adenosine-mediated immunosuppressive mechanisms are targeted, then immune response against tumor is enhanced, but treatment complexity increases
Solution Approach 1:
The patent extracts and isolates the specific adenosine A2a receptor pathway as the target for intervention. By focusing on this single dominant immunosuppressive mechanism rather than attempting to modulate the entire adenosinergic system or multiple immune pathways simultaneously, the treatment simplifies the therapeutic approach while effectively enhancing immune response against the tumor
Solution Approach 2:
The invention creates a simplified model of immune enhancement by using a small molecule antagonist that replicates the effect of blocking adenosine signaling. This single compound copies and amplifies the natural immune response without requiring complex combination therapies or multiple intervention points, reducing treatment complexity
Data Source
Figure 1a~1b
Figure 1c~2
Figure 3~4
AI summary
The present invention relates to 5-bromo-2,6-di-(1 H-pyrazol-1-yl)pyrimidin-4-amine, its pharmaceutically acceptable salts and co-crystals thereof and to pharmaceutical compositions comprising said compounds for use in the treatment of cancer.
